MBX Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

MBX$51.35+6.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Balance Sheets

(in thousands, except share and per share amounts)

	September 30,	December 31,
	2024	2023
(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$132,865	$30,523
Marketable securities	144,198	50,153
Prepaid expenses and other current assets	4,107	2,789
Total current assets	281,170	83,465
Property and equipment, net	1,033	439
Right-of-use assets	147	226
Other assets	50	50
Total assets	$282,400	$84,180
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$5,002	$1,391
Accrued expenses	5,752	2,382
Operating lease liability, current	166	153
Total current liabilities	10,920	3,926
Share repurchase liability	68	194
Operating lease liability, net of current	44	171
Total liabilities	11,032	4,291
Commitments and contingencies (Note 9)
Convertible preferred stock
Series A Convertible Preferred Stock, $0.0001 par value, zero shares authorized, issued and outstanding as of September 30, 2024 and 53,598,587 shares authorized, issued and outstanding (liquidation preference of $36,822,229) as of December 31, 2023	—	36,501
Series B Convertible Preferred Stock, $0.0001 par value, zero shares authorized, issued and outstanding as of September 30, 2024 and 129,240,032 shares authorized, issued and outstanding (liquidation preference of $116,316,029) as of December 31, 2023	—	115,856
Total convertible preferred stock	—	152,357
Stockholders’ equity (deficit)
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized and zero issued and outstanding as of September 30, 2024 and zero shares authorized, issued and outstanding as of December 31, 2023	—	—
Common stock, $0.0001 par value, 500,000,000 shares authorized and 33,376,058 issued and outstanding as of September 30, 2024 and 237,000,000 shares authorized and 1,257,080 issued and outstanding as of December 31, 2023	5	1
Additional paid-in-capital	393,176	3,054
Accumulated deficit	(121,919)	(75,583)
Accumulated other comprehensive income	106	60
Total stockholders’ equity (deficit)	271,368	(72,468)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$282,400	$84,180

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.